Safety profiles of Fe2+ and Fe3+ oral preparations in the treatment of iron deficiency anemia in children


KAVAKLI K. , YILMAZ D., CETINKAYA B., BALKAN C. , SOZMEN E. , Sagin F.

PEDIATRIC HEMATOLOGY AND ONCOLOGY, vol.21, no.5, pp.403-410, 2004 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 21 Issue: 5
  • Publication Date: 2004
  • Doi Number: 10.1080/08880010490457114
  • Title of Journal : PEDIATRIC HEMATOLOGY AND ONCOLOGY
  • Page Numbers: pp.403-410

Abstract

The major purpose of this study was to compare the oxidant-related toxicities of the different oral iron preparations in children with iron deficiency anemia (IDA); the second aim was to investigate the side effects of iron preparations. Seventy-two children with IDA were randomly included in the Fe2+ group (n = 39) or the Fe3+ group (n = 33). Some oxidizable substrates (erythrocytes malondialdehyde (MDA), urine 8-isoprostane, and basal and Cu-stimulated-oxidized LDL and antioxidant enzyme (superoxide dismutase (SOD), catalase and glutathione peroxidase) activities were evaluated at the beginning and at the 1st, 3rd, and 6th months of therapy. Side effects due to medication were recorded. While at the end of the 1st month SOD levels were significantly increased in Fe3+ group, at the 6th month evaluation, basal-oxidized LDL levels were significantly increased in the Fe3+ group, as was urine 8-isoprostane in the Fe2+ group. No other difference was found between two groups. In conclusion, there were minimal differences between children treated with ferric or ferrous iron in antioxidant system activities, the status of oxidizable substrates, and clinical toxicities.